Notice for Shareholders

Genexine, Inc. is excited to announce that a poster presentation at ASCO 2023 has been accepted for the HNSCC(Head and Neck Cancer) triple combo study of GX-I7, 188E and pembrolizumab

Here are a few key facts for your information.

• The trial is an ongoing Ph2 IIT(Investigator Initiated Trial) by prof. Hye-Ryun Kim of Severance Hospital, Yonsei univ. 
• Abstract will be available on ASCO website from May 25^th. 
• ASCO Annual Meeting will be held in Chicago, IL. from June 2^nd to 4^th

The company will share the abstract with the public once it is disclosed on ASCO website. 

Thank you. 

Genexine IR.